Health

Healthcare Economist Unbiased Analysis of Today’s Healthcare Issues

  • What makes patients switch doctors?
    by Jason Shafrin on August 22, 2025 at 5:50 am

    A paper by Dillibe et al. (2025), examined primary data obtained from 555 US-based patients who reported switching providers between 2018 and 2022. To analyze these data, the authors used critical incident technique (CIT). CIT is implemented by asking participants to recall and describe specific events or behaviors that contributed to important outcomes (in this…

  • Alcohol: Changing use and perceptions
    by Jason Shafrin on August 20, 2025 at 3:57 pm

    Conventional wisdom holds that alcohol use is part of American culture…but perhaps this is changing. According to a Gallup poll released last week, not only is alcohol use declining but there is an increasing perception that alcohol use is not good for you. While a majority of Americans (54%) still use alcohol, drinking rates are…

  • Impact of Medicare Part B on pharmaceutical price growth
    by Jason Shafrin on August 19, 2025 at 1:37 am

    Does Medicare Part B increase or decrease the prices of physician-administered drugs relative to physician-administered drugs covered by private insurance? That is the question a paper by Acquatella, Ericson and Starc (2023) aim to answer. Before we answer that question, we first need to understand how Part B works, how physicians are reimbursed, and how…

  • Will most favored nation reduce drug prices in the US…or raise prices in Europe?
    by Jason Shafrin on August 15, 2025 at 2:16 pm

    The answer seems to be the latter. The Times (UK) reports. Eli Lilly, the US-based manufacturer of Mounjaro, said it was hiking the UK list price for the medication from September 1 to bring it in line with other nations…Eli Lilly is increasing the amount it charges pharmacies. The rate for a middle-sized 5mg dose…

  • President Trump’s demand letter: What is he asking pharmaceutical companies to do?
    by Jason Shafrin on August 14, 2025 at 3:42 pm

    On July 31, President Trump sent letters to some of the largest pharmaceutical companies in the world (AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron, and Sanofi) asking them to fundamentally change drug pricing in the US. What was…